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ABSTRACT
Background: The outbreak of coronavirus disease 2019 (COVID-19) has globally strained medical
resources and caused significant mortality.
Objective: To develop and validate a machine-learning model based on clinical features for severity risk
assessment and triage for COVID-19 patients at hospital admission.
Method: 725 patients were used to train and validate the model. This included a retrospective cohort from
Wuhan, China of 299 hospitalised COVID-19 patients from 23 December 2019 to 13 February 2020, and
five cohorts with 426 patients from eight centres in China, Italy and Belgium from 20 February 2020 to 21
March 2020. The main outcome was the onset of severe or critical illness during hospitalisation. Model
performances were quantified using the area under the receiver operating characteristic curve (AUC) and
metrics derived from the confusion matrix.
Results: In the retrospective cohort, the median age was 50 years and 137 (45.8%) were male. In the five
test cohorts, the median age was 62 years and 236 (55.4%) were male. The model was prospectively
validated on five cohorts yielding AUCs ranging from 0.84 to 0.93, with accuracies ranging from 74.4% to
87.5%, sensitivities ranging from 75.0% to 96.9%, and specificities ranging from 55.0% to 88.0%, most of
which performed better than the pneumonia severity index. The cut-off values of the low-, medium- and
high-risk probabilities were 0.21 and 0.80. The online calculators can be found at www.covid19risk.ai.
Conclusion: The machine-learning model, nomogram and online calculator might be useful to access the
onset of severe and critical illness among COVID-19 patients and triage at hospital admission.
This article has supplementary material available from erj.ersjournals.com
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Introduction
In December 2019, a novel coronavirus, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2;
earlier named as 2019-nCoV), emerged in Wuhan, China [1]. The disease caused by SARS-CoV-2 was
named coronavirus disease 2019 (COVID-19). As of 15 May 2020, more than 4490000 COVID-19
patients have been reported globally, and over 300000 patients have died [2]. The outbreak of COVID-19
has developed into a pandemic [3].
Among COVID-19 patients, around 80% present with mild illness whose symptoms usually disappear
within 2 weeks [4]. However, around 20% of the patients may proceed and necessitate hospitalisation and
increased medical support. The mortality rate for severe patients is around 13.4% [4]. Therefore, risk
assessment of patients preferably in a quantitative, non-subjective way is extremely important for patient
management and medical resource allocation. General quarantine and symptomatic treatment at home or
mobile hospitals can be used for most non-severe patients, while a higher level of care and fast track to the
intensive care unit (ICU) is needed for severe patients. Previous studies have summarised the clinical and
radiological characteristics of severe COVID-19 patients, while the prognostic value of different variables is
still unclear [5, 6].
Several scoring systems that are in common clinical use (e.g. Sequential Organ Failure Assessment score;
Confusion, Urea, Respiratory rate, Blood pressure, Age 65; Acute Physiology and Chronic Health
Evaluation, etc.) could be applied to the triage problem, albeit each with their own problems and
limitations, such as the need for laboratory variables that are hard to obtain at hospital admission [7]. The
pneumonia severity index (PSI) stands out as it is used to assess the probability of severity and mortality
among adult patients with community-acquired pneumonia and to help hospitalisation management [8].
A better solution could possibly be found using machine learning, a branch of artificial intelligence that
learns from past data in order to build a prognostic model [9]. In recent years, machine learning has been
developed as a useful tool to analyse large amounts of data from medical records or images [10]. Previous
modelling studies focused on forecasting the potential international spread of COVID-19 [11].
Therefore, our objective is to develop and validate a prognostic machine-learning model based on clinical,
laboratory and radiological variables of COVID-19 patients at hospital admission for severity risk
assessment during hospitalisation, and compare the performance with that of PSI as a representative
clinical assessment method. Our ambition is to develop a multifactorial decision support system with
different datasets to facilitate risk prediction and triage (home or mobile hospital quarantine,
hospitalisation or ICU) of the patient at hospital admission.
Methods
Patients
The institutional review board approved this study (2020-71), which followed the Standards for Reporting
of Diagnostic Accuracy Studies statement [12], and the requirement for written informed consent was
waived. 299 adult confirmed COVID-19 patients from the central hospital of Wuhan, China were included
consecutively and retrospectively between 23 December 2019 and 13 February 2020. The inclusion criteria
were: 1) patients with confirmed COVID-19 disease; and 2) patients presenting at hospital for admission.
The exclusion criteria were: 1) patients who already had a severe illness at hospital admission; 2) time
interval>2 days between admission and examinations; and 3) no data available or delayed results as described
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below. The patients included from this centre were divided into two datasets according to the entrance time
of hospitalisation, 80% for training (239 patients from 23 December 2019 to 28 January 2020) and 20% for
internal validation (60 patients from 29 January to 13 February 2020). The five test datasets were collected
between 20 February 2020 and 31 March 2020 from other eight centres (supplementary material) in China,
Italy and Belgium under the same inclusion and exclusion criteria (figure 1).
Patients were labelled as having a “severe disease” if at least one of the following criteria were met during
hospitalisation [6, 13]: 1) respiratory failure requiring mechanical ventilation; 2) shock; 3) ICU admission;
4) organ failure; or 5) death. Patients were labelled as having a “non-severe disease” if none of the above
mentioned criteria were met during the whole hospitalisation process until deemed recovered and
discharged from the hospital.
Data collection
Clinical, laboratory and radiological characteristics, and outcome data were obtained from the case record
form shared by the International Severe Acute Respiratory and Emerging Infection Consortium from the
electronic medical records [14]. A confirmed case with COVID-19 was defined as a positive result of
high-throughput sequencing or real-time reverse-transcriptase PCR assay for nasal and pharyngeal swab
specimens. After consultation with respiratory specialists and review of the recent COVID-19 literature, a
set of clinical, laboratory and radiological characteristics was identified and data collected from the
electronic medical system. The clinical characteristics included basic information (five variables),
comorbidities (11 variables) and symptoms (13 variables). All clinical characteristics were obtained when
the patients were admitted to hospital for the first time. 42 laboratory results were recorded, including
complete blood count, white blood cell differential count, D-dimer, C-reactive protein (CRP), cardiac
enzymes, procalcitonin, liver function test, kidney function test, B-type natriuretic peptide and electrolyte
test. The arterial blood gas was not taken into account due to missing data for most early-stage patients.
The metric conversion of laboratory results was performed using an online conversion table [15]. A
detailed list of variables can be found in tables 1 and 2.
The semantic computed tomography (CT) characteristics (including ground-glass opacity, consolidation,
vascular enlargement, air bronchogram and lesion range score) were independently evaluated on all
datasets by two radiologists (P. Yang, a radiologist with 5 years’ experience in chest CT images, and Y. Xie,
a radiologist with 20 years’ experience in chest CT images), who were blinded to clinical and laboratory
results. Any disagreement was resolved by a consensus read. Lesion range was identified as areas of
ground-glass opacity or consolidation and was graded with a six-point scale according to the lesion
volume proportion in each single lobe: 0=no lung parenchyma involved; 1=up to 5% of lung parenchyma
Test 5 (n=178)
Non-severe (n=80); severe (n=98)
From Liège, Belgium




Non-severe (n=40); severe (n=50)
From Genoa and Rome, Italy
Test 3 (n=32)
Non-severe (n=25); severe (n=7)
From outside Hubei province, China
Test 2 (n=90)
Non-severe (n=41); severe (n=49)
From outside Wuhan in Hubei province
Test 1 (n=36)
Non-severe (n=20); severe (n=16)







Patients excluded due to 
severe illness at admission 
(n=14)
Patients excluded due to
missing data
(n=38)
Patients excluded due to time 
interval >2 days between the 
admission and examinations
(n=13)
FIGURE 1 Flowchart of the patient selection process. COVID-19: coronavirus disease 2019; RT-PCR: reverse
transcriptase-PCR.
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involved; 2=5–25%; 3=26–50%; 4=51–75%; and 5=76–100% of lung parenchyma involved. The lesion
volume proportion was automatically calculated by the Pneumonia Assisted Diagnosis System (version
1.17.0; Shukun Technology), and the final score was the total score from five lobes (figure 2). Detailed CT
acquisition and reconstruction parameters are presented in the supplementary material.
Feature selection and modelling
All feature selection and model training were performed in the training dataset alone to prevent
information leakage. An overview of the functions used is given in table S1. In order to reduce feature
dimensionality, features showing high pairwise Spearman correlation (r=>0.8) and the highest mean
correlation with all remaining features were removed, followed by application of the Boruta algorithm to
select important features [16]. The Boruta algorithm combines feature rank based on the random forest
classification algorithm and selection frequency based on multiple iterations of the feature selection
procedure. Recursive feature elimination based on bagged tree models with a cross-validation technique
TABLE 1 Clinical characteristics and radiological findings of patients confirmed with
coronavirus disease 2019
Non-severe group Severe group p-value#
Subjects n 228 71
Age years 43.0 (33.0–61.0) 62.0 (52.5–71.5) <0.001
Males 95 (41.7) 42 (59.2) 0.014
Smoking history 17 (7.5) 14 (19.7) 0.006
Hospital staff 86 (37.7) 4 (5.6) <0.001
Time of onset of illness days 4.0 (2.0–7.0) 4.0 (2.0–7.0) 0.963
Comorbidities
Hypertension 44 (19.3) 31 (43.7) <0.001
Diabetes 19 (8.3) 18 (25.4) <0.001
Hyperlipidaemia 11 (4.8) 5 (7.0) 0.545
Cardiopathy disease 2 (0.88) 8 (11.3) <0.001
COPD 8 (3.5) 13 (18.3) <0.001
Cerebrovascular disease 6 (2.6) 16 (22.5) <0.001
Kidney disease 5 (2.2) 11 (15.5) <0.001
Fatty liver 28 (12.3) 12 (16.9) 0.322
Hepatitis B virus carrier 2 (0.88) 5 (7.0) 0.009
Cancer history 12 (5.3) 4 (5.6) 1
Surgical history 30 (13.2) 15 (21.1) 0.127
Symptoms
Fever 172 (75.4) 47 (66.2) 0.128
Body temperature C 37.8 (37.3–38.4) 37.5 (36.8–38.0) 0.027
Cough 153 (67.1) 46 (64.8) 0.774
Sputum 59 (25.9) 25 (35.2) 0.133
Weakness 102 (44.7) 31 (43.7) 0.892
Diarrhoea 25 (11.0) 8 (11.3) 1
Vomiting 16 (7.0) 9 (12.7) 0.144
Chest tightness 50 (21.9) 30 (42.3) 0.001
Dyspnoea 11 (4.8) 4 (5.6) 0.760
Muscular soreness 61 (26.8) 17 (23.9) 0.757
Chill 38 (16.7) 11 (15.5) 1
Conjunctival congestion 1 (0.44) 1 (1.4) 0.419
Headache or dizziness 34 (14.9) 12 (16.9) 0.708
Radiological findings
Main findings 0.928
Normal 4 (1.8) 1 (1.4)
Ground-glass opacity only 132 (57.9) 39 (54.9)
Consolidation only 22 (9.6) 6 (8.5)
Mixed 70 (30.7) 25 (35.2)
Vascular enlargement 66 (28.9) 36 (50.7) <0.001
Air bronchogram 49 (21.5) 30 (42.3) 0.001
Lesion range score 4.5 (2.0–7.0) 6.0 (4.0–10.5) 0.001
Data are presented median (interquartile range) or n (%), unless otherwise stated. #: obtained using
Fisher’s exact test or Mann–Whitney U-test.
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(10 folds, 10 times) was performed to select the best performing combination of features. In order to
balance the positive and negative sample size, an adaptive synthetic sampling approach for imbalanced
learning (ADASYN) was used during feature selection and modelling [17]. The feature selection process
was used for clinical, laboratory and CT semantic models alone, and in combination.
Logistic regression models based on selected features were trained and the validation dataset was used to
internally validate the prognostic performance of the models. Four models were trained: model 1
contained only baseline clinical features without symptoms; model 2 used all selected clinical features;
TABLE 2 Laboratory results of patients with coronavirus disease 2019 at hospital admission
Laboratory results Non-severe group Severe group p-value#
Subjects n 228 71
Complete blood cell count
White blood count ×10⁹ cells·L−1 4.5 (3.3–5.8) 5.5 (4.0–7.6) <0.001
Red blood cell count ×1012 cells·L−1 4.4 (4.1–4.7) 4.3 (4.0–4.7) 0.217
Haemoglobin g·L−1 130.5 (121.0–142.0) 132.0 (117.0–142.5) 0.968
Platelets ×10⁹ cells·L−1 174.0 (140.8–214.5) 149.0 (116.5–183.5) <0.001
Haematocrit % 39.5 (36.6–42.7) 38.9 (36.0–42.6) 0.472
Mean corpuscular volume fL 90.5 (87.5–93.4) 90.5 (87.8–94.7) 0.526
Mean corpuscular haemoglobin pg 30.0 (28.7–30.9) 30.0 (29.1–31.5) 0.266
Mean corpuscular haemoglobin concentration g·dL−1 330.0 (323.0–336.0) 329.0 (323.0–337.0) 0.684
Red blood cell distribution width standard deviation fL 39.1 (36.4–41.1) 40.0 (15.3–41.7) 0.193
Red blood cell distribution width coefficient of variation % 12.7 (12.1–14.9) 13.0 (12.5–38.3) 0.015
Platelet distribution width % 12.9 (10.7–16.3) 12.4 (10.8–15.8) 0.371
Platelet large cell ratio % 24.0 (19.7–30.1) 26.8 (21.1–32.3) 0.028
Mean platelet volume fL 9.8 (9.2–10.6) 10.2 (9.4–10.9) 0.016
Thrombocytocrit % 0.17 (0.14–0.21) 0.15 (0.13–0.18) 0.002
White cell differential count
Neutrophil % 64.5 (56.6–74.7) 76.3 (67.1–85.7) <0.001
Lymphocyte % 26.1 (17.8–26.8) 15.3 (7.6–22.8) <0.001
Monocyte % 7.7 (5.7–9.8) 6.9 (4.5–8.9) 0.061
Eosinophil % 0.10 (0.00–0.60) 0.00 (0.00–0.31) 0.007
Basophil % 0.20 (0.10–0.30) 0.20 (0.10–0.30) 0.558
Neutrophil count ×10⁹ cells·L−1 2.9 (1.9–3.9) 4.2 (2.7–6.1) <0.001
Lymphocyte count ×10⁹ cells·L−1 1.1 (0.78–1.5) 0.77 (0.49–1.14) <0.001
Monocyte count ×10⁹ cells·L−1 0.33 (0.24–0.44) 0.37 (0.23–0.52) 0.215
Eosinophil count ×10⁹ cells·L−1 0.01 (0.00–0.03) 0.00 (0.00–0.01) 0.087
Basophil count ×10⁹ cells·L−1 0.01 (0.01–0.01) 0.01 (0.01–0.02) 0.364
D-dimer mg·L−1 0.45 (0.24–0.90) 0.73 (0.46–1.83) <0.001
C-reactive protein mg·dL−1 1.4 (0.46–3.1) 3.9 (2.4–7.2) <0.001
Cardiac enzymes
Aspartate amino transferase U·L−1 22.1 (17.3–31.1) 33.6 (22.2–42.8) <0.001
Alpha-hydroxybutyric dehydrogenase U·L−1 143.0 (113.0–174.1) 189.0 (157.5–268.5) <0.001
Lactate dehydrogenase U·L−1 183.5 (142.8–231.2) 252.0 (199.7–331.8) <0.001
Creatine kinase U·L−1 78.5 (45.0–132.4) 108.4 (59.8–248.0) 0.001
Liver function
Alanine aminotransferase U·L−1 21.6 (13.4–33.4) 25.8 (15.7–38.8) 0.202
Aspartate transaminase U·L−1 22.3 (17.1–31.2) 31.1 (21.0–40.1) <0.001
Gamma-glutamyl transpeptidase U·L−1 22.3(13.7–42.8) 36.8 (22.7–51.5) <0.001
Kidney function
Urea mmol·L−1 4.1 (3.2–5.1) 6.3 (4.6–8.2) <0.001
Creatinine μmol·L−1 64.7 (52.8–75.1) 77.3 (63.8–90.8) <0.001
Procalcitonin ng·mL−1 0.05 (0.04–0.09) 0.11 (0.06–0.31) <0.001
B-type natriuretic peptide pg·mL−1 59.4 (22.4–106.7) 156.0 (56.4–486.7) <0.001
Electrolyte
Potassium mmol·L−1 4.1 (4.0–4.3) 4.1 (3.8–4.3) 0.353
Sodium mmol·L−1 141.1 (140.0–142.2) 139.9 (137.8–141.5) <0.001
Chloride mmol·L−1 103.9 (102.5–105.6) 102.7 (100.9–105.1) 0.006
Calcium mmol·L−1 2.3 (2.2–2.4) 2.2 (2.1–2.3) <0.001
Phosphate mmol·L−1 1.0 (0.9–1.1) 0.95 (0.80–1.1) 0.005
Data are presented as median (interquartile range), unless otherwise stated. #: obtained using Mann–Whitney U-test.
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model 3 used selected semantic CT features, age and sex; and model 4 employed all selected clinical,
laboratory and CT features.
The prognostic performances of the best model were compared with other models on the training dataset,
due to a bigger sample size. The performance of the best model and PSI scoring were gauged on the
datasets via the receiver operator characteristic (ROC) and confusion matrix. In order to gauge the level of
overfitting, the outcomes were randomised on the best model and the entire process repeated, from feature
selection to model building and evaluation.
The patients from the training datasets were divided into low, medium and high risk according to the first
quartile (25th percentile) and the third quartile (75th percentile) of probabilities from the best performing
model. Nomograms and online calculators were used to provide the interpretability of the best trained
models. The test datasets were used to gauge the prognostic performance and the validity for the best model.
Statistical analysis
Baseline data were summarised as median, and categorical variables as frequency (%). Differences between
the severe group and the non-severe group were tested using the Mann–Whitney test for continuous data
and Fisher’s exact test for categorical data. Feature correlations were measured using the Spearman
correlation coefficient. We determined the area under the ROC curve (AUC) with its 95% CI and tested
AUC difference between models 1–3 and model 4 using the method of DELONG et al. [18], measures of
prognostic performance including the AUC and metrics derived from the confusion matrix accuracy,
sensitivity, specificity, positive prediction value (PPV) and negative prediction value (NPV). A
calibration-plot based on the Hosmer–Lemeshow test was used to estimate the goodness-of-fit and
consistency of the model on the test datasets. All p-values were two-sided and p<0.05 was regarded as
significant. All statistical analyses, modelling and plotting were performed in R (version 3.5.3), and the
detailed package characteristics are listed in table S1.
Results
Demographic and clinical characteristics
Out of 299 hospitalised COVID-19 patients in the retrospective cohort, the median (interquartile range)
age was 50 (35.5–63.0) years and age range was 20–94 years. 137 (45.8%) were male. All the clinical
characteristics and CT findings are summarised in table 1, and more details of laboratory findings can be
a)
b)
FIGURE 2 Chest computed tomography images of two patients with coronavirus disease 2019 pneumonia.
a) A 48-year-old man, the focal ground-glass opacities in the bilateral lung lobes (yellow arrow) were
automatically segmented (orange areas) and the lesion volume in each lobe was calculated: right superior
lobe: 0.2%; right middle lobe: 0.3%; right inferior lobe: 0.1%; left superior lobe: 0.9%; and left inferior lobe:
9.4%. The lesion range score was 6 (1+1+1+1+2). b) A 70-year-old man, the peripheral ground-glass opacities
in the bilateral lung lobes (yellow arrow) were automatically segmented (orange areas) and the lesion volume
in each lobe was calculated: right superior lobe: 32.1%; right middle lobe: 16.4%; right inferior lobe: 62.7%;
left superior lobe: 12.8%; and left inferior lobe: 7.3%. The lesion range score was 13 (3+2+4+2+2).
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seen in table 2. Out of 426 hospitalised COVID-19 patients in five cohorts as test datasets, the median
(interquartile range) age was 62 (50.0–72.0) years and age range was 19–94 years. 236 (55.4%) were male.
Feature selection
Among the clinical features, age, hospital employment, body temperature and the time of onset to
admission were selected. Lymphocyte (proportion), neutrophil, (proportion), CRP, lactate dehydrogenase
(LDH), creatine kinase, urea and calcium were selected from the laboratory feature set. Only the lesion
range score was selected from CT semantic features. When putting these three category features together
to select features, age, lymphocyte (proportion), CRP, LDH, creatine kinase, urea and calcium were finally
included in the combination model.
Models performance in the training and validation dataset
Model performance was as follows. Model 1 was based on age and hospital employment and showed an
AUC of 0.74 (95% CI 0.69–0.79) on the training dataset and 0.83 (95% CI 0.72–0.94) on the validation
dataset. Model 2 with the clinical features of age, hospital employment, body temperature and the time of
onset yielded an AUC of 0.78 (95% CI 0.73–0.83) on the training dataset and 0.74 (95% CI, 0.59–0.89) on
the validation dataset. Model 3 was based on age and lesion range score on CT and had an AUC of 0.75
(95% CI 0.70–0.80) on the training dataset and 0.83 (95% CI, 0.72–0.94) on the validation dataset.
When pooling these three categories of features, the combination model (model 4) selected seven features
(age, lymphocyte (proportion), CRP, LDH, creatine kinase, urea and calcium), which achieved the highest
AUC of 0.86 (95% CI 0.82–0.90) on the training dataset and a 0.90 (95% CI 0.82–0.98) on the validation
dataset. The AUC value of model 4 was significantly higher than model 1 (p=0.001), model 2 (p=0.033)
and model 3 (p=0.003) on the training dataset. The cut-off values from reclassification of low-, medium-
and high-risk probabilities were 0.21 and 0.80.
External validation
Model 4 was validated on the five test datasets, which showed AUCs ranging from 0.84 to 0.93 with
accuracies ranging from 74.4% to 87.5%, sensitivities ranging from 75.0% to 96.9%, specificities ranging
from 55.0% to 88.0%, PPVs ranging from 66.7% to 84.1%, and NPVs ranging from 73.9% to 95.7%
(table 3). The ROC, confusion matrix and calibration plots are shown in figure 3. The results of
randomising the outcomes and re-running the analysis yielded an AUC of 0.50 (95% CI 0.44–0.55) for
model 4.
Clinical use
Based on the selected features from the best models, a nomogram was established to quantitatively assess
the severity risk of illness (figure 4). The developed online calculators can be found at www.covid19risk.ai.
Compared to PSI scoring (cut-off value: 90), model 4 (cut-off value: 0.53) showed higher AUCs,
accuracies, sensitivities and NPVs on the five test datasets (table 3). There was significant difference for
the proportion of severe patients among low-, medium- and high-risk groups in the five test datasets
(figure 5).
TABLE 3 The prognostic performance of the combination model (model 4) on five test datasets
Dataset Tool AUC (95% CI) Accuracy (95% CI) % Sensitivity % Specificity % PPV % NPV %
Test 1 Model 0.88 (0.75–1.0) 80.6 (64.0–91.8) 75.0 85.0 80.0 81.0
PSI 0.87 (0.74–1.0) 77.8 (60.9–89.9) 56.3 95.0 90.0 73.1
Test 2 Model 0.88 (0.80–0.95) 78.9 (69.0–86.8) 75.5 82.9 84.1 73.9
PSI 0.86 (0.79–0.94) 65.6 (54.8–75.3) 38.8 97.6 95.0 57.1
Test 3 Model 0.93 (0.83–1.0) 87.5 (71.0–96.5) 85.7 88.0 66.7 95.7
PSI 0.89 (0.77–1.0) 75.0 (56.6–88.5) 0.00 96.0 0.00 77.4
Test 4 Model 0.84 (0.76–0.93) 74.4 (64.2–83.1) 90.0 55.0 71.4 81.5
PSI 0.78 (0.68–0.87) 67.8 (57.1–77.3) 62.2 73.3 70.0 66.0
Test 5 Model 0.89 (0.85–0.94) 79.2 (72.5–84.9) 96.9 57.5 73.6 93.9
PSI 0.71 (0.63–0.78) 62.9 (55.4–70.0) 42.9 87.5 80.8 55.6
Mean (Test 1–5) Model 0.88 80.1 84.6 73.7 75.2 85.2
PSI 0.82 69.8 40.0 89.9 67.2 65.8
PSI: pneumonia severity index; AUC: area under the receiver operating characteristic curve; PPV: positive prediction value; NPV: negative
prediction value.
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Discussion
This international multicentre study analysed individually and in combination, clinical, laboratory and
radiological characteristics for COVID-19 patients at hospital admission to retrospectively develop and
prospectively validate a prognostic model and tool to assess the severity of the illness, and its progression,
and to compare these with PSI scoring. We found that COVID-19 patients who developed a severe illness
were often of an advanced age, had multiple comorbidities, presented with chest tightness, and had
abnormal laboratory results and broader lesion range on lung CT on admission. Using simpler linear
regression models yielded better prognostic performance than PSI scoring in the test datasets. We believe
these models could be useful for risk assessment and triage.
Previous studies have reported that age and underlying comorbidities (such as hypertension, diabetes and




















































































































FIGURE 3 The a) receiver operator characteristic curve, b) confusion matrix and c) calibration curve for the test datasets. AUC: area under the
curve.
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FIGURE 4 Severe-illness risk nomogram and triage tool for clinicians.
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In this study, we found that the elderly COVID-19 patients who were male, non-hospital staff, suffering
from hypertension, diabetes, cardiopathy disease, COPD, cerebrovascular disease, renal disease, hepatitis B
virus infection, lower body temperature and chest tightness were more vulnerable to develop a severe
illness in the early stages of the disease. Among these features, age, hospital staff, body temperature and
the time of onset to admission had certain prognostic abilities. Age was the most important feature, which
may interact with other features, which was why only age was selected into our combination model (model
4) from these features. ZHOU et al. [21] have confirmed that SARS-CoV-2 uses the same cell entry receptor
(angiotensin-converting enzyme-2) as SARS-CoV. However, whether COVID-19 patients with
hypertension and diabetes have higher severe illness risk, which is due to treatment with
angiotensin-converting enzyme-2, increasing drugs is still unknown [22]. Hospital staff had a lower risk of
progression, possibly due lower age, higher levels of education, and more medical knowledge once
infected, although the unbalanced nature of this type of data has to be taken into account.
Furthermore, early studies have shown that COVID-19 patients with severe illness had more laboratory
abnormalities such as CRP, D-dimer, lymphocytes, neutrophils and LDH, than those patients with
non-severe illness, which were associated with the prognosis [19, 20, 23]. In our study, we also found that
the severe group had numerous laboratory abnormalities in complete blood cell count, white cell
differential count, D-dimer, CRP, liver function, renal function, procalcitonin, B-type natriuretic peptides
and electrolytes. Among these abnormalities, lymphocyte proportion, neutrophil proportion, CRP, LDH,
creatine kinase, urea and calcium were significant prognostic factors, which suggest that COVID-19 may
cause damage to multiple organ systems when developing into a severe illness. However, current
pathological findings of COVID-19 suggest that there is no evidence that SARS-CoV-2 can directly impair
the other organs such as liver, kidney and heart [24].
Current reports have shown that thin-slice chest CT is a powerful tool in clinical diagnosis due to the high
sensitivity and the ability to monitor the development of the disease [25, 26]. In addition, a previous study
reported that ground-glass opacity and consolidation were the most common CT findings for COVID-19
patients with pneumonia, while being nonspecific [27]. Clinical observations showed that there were
significantly more consolidation lesions in ICU patients on admission, while more ground-glass opacity
lesions were observed in non-ICU patients [28]. In our study, we found that vascular enlargement, air
bronchogram and lesion range score differed significantly between non-severe and severe groups. Among
these features, only the lesion range score had prognostic power, but not enough to be selected for the
combination model. This indicates that while these early stage CT semantic features could have diagnostic
value, they have limited ability to prognose the onset of severe illness in COVID-19 patients.
The Chinese National Health Committee added some warning indicators for severe or critical cases in the
updated diagnosis and treatment plan for COVID-19 patients (version 7) [29], which includes progressive
reduction of peripheral blood lymphocytes, a progressive increase of interleukin-6, CRP and lactate, and
rapid progression of lung CT findings in a short period. In this study, we used age, lymphocyte fraction,
CRP, LDH, creatine kinase, urea and calcium scores from clinical, laboratory, and radiological
examinations recorded at hospital admission to train a model for the prediction of the onset of severe
illness. Our model combining these features from multiple sources showed a favourable performance when
validated in the five external datasets from China, Italy and Belgium. In addition, the model is able to
stratify COVID-19 patients into low-, medium- and high-risk groups for developing severe illness. We
propose that this model, with its higher prediction performance and simplicity than PSI score, could be
FIGURE 5 Histogram plot of the
proportion of severe patients in
low-, medium- and high-risk
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used for a preliminary screening and triage tool at hospital admission for the potential to develop severe
illness. Furthermore, the model could be used for the selection and/or stratification of patients in clinical
trials in order to homogenise the patient population. Follow-up laboratory tests are needed to assess the
severity risk with a higher accuracy.
As one of the coronavirus family’s infecting humans, SARS-CoV-2 has similar aetiologic, clinical,
radiological and pathological features to those of severe acute respiratory syndrome coronavirus and
Middle East Respiratory Syndrome coronavirus [23, 30, 31]. Therefore, we believe that developing a
reliable early warning model based on present clinical, radiological and pathological data is necessary for
current outbreaks and possible future outbreaks of coronaviruses.
Our study has several limitations. First, selection bias is unavoidable as is the limited and unbalanced
sample size. Secondly, patients from different races and ethnicities may have diverse clinical and laboratory
results, and the self-medication of patients before admission may affect the clinical and laboratory results.
Thirdly, the threshold to go to the hospital and hospitalisation management can vary from country to
country, and we are also aware that RNA viruses can mutate rapidly and could have an impact of the
performance of the models. We therefore propose that those models should be continuously updated to
achieve a better performance for example using privacy preserving distributed learning approaches [32,
33]. Fourthly, the CT features used for this study are semantic features from the first CT scan, and
radiomics or deep learning approaches may improve its prognostic performance, and follow-up CT scans
may yield more information. Finally, due to the large number of predictors included in the analysis, and
the complexity of feature selection and modelling, overfitting is always possible. We have mitigated this
with the use of external validation cohorts, and by re-running the analysis on randomised outcomes to
arrive at a “chance” (AUC=0.5) result.
Conclusions
Elderly COVID-19 patients and non-hospital staff seem more vulnerable to develop a severe illness after
hospitalisation as per defining criteria, which can cause a wide range of laboratory and CT anomalies.
Furthermore, our model based on lactate dehydrogenase, C-reactive protein, calcium, age, lymphocyte
proportion, urea and creatine kinase might be a more useful preliminary screening and triage tool than
pneumonia severity index for risk assessment of COVID-19 patients at hospital admission.
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